Navigation Links
Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
Date:10/24/2011

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing Phase 2 clinical trial in patients with stage IV previously untreated pancreatic cancer. The poster and abstract will also be published in the "European Journal of Cancer" proceeding book of the conference. Details of the poster session and discussion are as follows:

Thursday, October 27, 2011

12:00 – 8:30 p.m. CET: Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors   (Discussion from 6:00 – 8:30 p.m. CET)

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Hercept
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  The Partnership to Fight Chronic Disease (PFCD) released a public opinion ... a new study analyzing the impact of increased cost sharing on ... working to educate policy makers and the public on the costs ... on how the Iowa healthcare exchange could ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
(Date:1/23/2015)... More than a third of reproductive-aged women enrolled in Medicaid, ... filled a prescription for an opioid pain medication each year ... and Mortality Weekly Report (MMWR). Opioids are ... severe pain.  They are also found in some prescription cough ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... MOUNTAIN VIEW, Calif., March 7, 2011 IRIDEX Corporation (Nasdaq: ... to make an investor presentation at the ROTH 23rd Annual ... pm Pacific Time.  The conference is being held March 13-16 ... The presentation will be accessible by live webcast ...
... Grifols, a global healthcare company and biopharmaceutical manufacturer ... established an Expert Advisory Council in Transfusion Medicine drawing ... from across the globe.  The role of the Expert ... to Grifols, own transfusion medicine research and development activities. ...
Cached Medicine Technology:Grifols Establishes Expert Advisory Council in Transfusion Medicine 2Grifols Establishes Expert Advisory Council in Transfusion Medicine 3
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... D.C. Areas of the brain responsible for ... patients who exercised following a medication holiday, say ... say the changes indicate brain functioning is more ... the brains resources is devoted to processing bothersome ...
... SUNDAY, Nov. 13 (HealthDay News) -- When added to standard ... people with "acute coronary syndrome" lower their risk of death, ... Acute coronary syndrome is an umbrella term that includes people ... finding "opens up a new area for treating this very ...
... study has identified a novel gene mutation that appears ... cases of malignant melanoma, the most deadly form of ... gene encoding MITF, a transcription factor that induces the ... in which melanoma originates. While previous research has ...
... A wearable defibrillator can prevent sudden death in people ... the American Heart Association,s Scientific Sessions 2011. , Wearable ... at higher risk for sudden cardiac arrest, including those ... a condition that prevents or delays them from receiving ...
... women with breast cancer have taken the drug tamoxifen, only ... tumors do not respond to the treatment at all, or ... at the University of California, San Francisco (UCSF) have discovered ... way to defeat it. On Sunday, Nov. 13, ...
... (HealthDay News) -- All U.S. children between the ages of ... to new guidelines endorsed by the nation,s leading group of ... guidelines that suggest such testing be done only for children ... blood cholesterol, which is one of the major risk factors ...
Cached Medicine News:Health News:Improved memory efficiency seen after aerobic exercise in fibromyalgia patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 4Health News:Newly identified gene mutation adds to melanoma risk 2Health News:Newly identified gene mutation adds to melanoma risk 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2Health News:Tamoxifen resistance -- and how to defeat it 2Health News:Tamoxifen resistance -- and how to defeat it 3Health News:Tamoxifen resistance -- and how to defeat it 4Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 3Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 4
200 L, Bulk, yellow Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
The Finntip 20 is suitable for applications requiring high precision and volumes of 0.2-20 ul. The tips are provided in convenient racks of 384 tips....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
Medicine Products: